Original Research
Published on 01 Sep 2025
Evaluating the toxicity profile of combination immune checkpoint inhibitors: a disproportionality analysis of real-world adverse events from the FDA Adverse Event Reporting System for tremelimumab, durvalumab, ipilimumab, and nivolumab
in Cancer Immunity and Immunotherapy
- 299 views